Ju Liu

发表

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.

K. G. Rajeev, M. Manoharan, A. Akinc, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis

W. Tan, D. Lin, Dianke Yu, 2008, Clinical Cancer Research.

Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry.

S. Chong, K. Charissé, C. Tran, 2019, Bioanalysis.

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

K. G. Rajeev, M. Manoharan, A. Akinc, 2017, Nucleic acids research.

The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

M. Manoharan, S. Chong, K. Charissé, 2022, Drug Metabolism and Disposition.

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

M. Manoharan, S. Chong, K. Charissé, 2022 .

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates

K. G. Rajeev, M. Manoharan, A. Akinc, 2019, Nucleic acids research.

Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways.

K. G. Rajeev, M. Manoharan, M. Egli, 2023, Journal of medicinal chemistry.

The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

M. Manoharan, S. Chong, K. Charissé, 2021, Drug Metabolism and Disposition.

Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity.

Yongfeng Jiang, Maja M. Janas, Pia V Kasperkovitz, 2016, Nucleic acid therapeutics.

Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic

S. Chong, C. Tran, Valerie A. Clausen, 2021, Drug Metabolism and Disposition.

Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic

S. Chong, C. Tran, Valerie A. Clausen, 2021, Drug Metabolism and Disposition.

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

M. Manoharan, S. Chong, K. Charissé, 2022 .

Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide in vivo by mass spectrometry.

K. Charissé, C. Tran, Jonathan O’Shea, 2019, Bioanalysis.

Systematically identifying genetic signatures including novel SNP-clusters, nonsense variants, frame-shift INDELs, and long STR expansions that potentially link to unknown phenotypes existing in dog breeds

J. Hoh, Zuoheng Wang, J. Lichtman, 2023, BMC Genomics.